Welcome to our dedicated page for LifeMD SEC filings (Ticker: LFMDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeMD, Inc. filings document the formal disclosures for the virtual primary care company and its listed securities, including common stock and the 8.875% Series A Cumulative Perpetual Preferred Stock. Form 8-K reports cover operating results, financial condition, earnings guidance, Regulation FD investor presentations, and executive officer changes.
Definitive proxy materials describe annual meeting procedures, board and governance matters, compensation-related disclosures, and stockholder voting items. The filing record also identifies the preferred security within the company's capital structure, including matters relevant to LFMDP holders such as preferred-stock status and related public-company disclosures.
LifeMD insider stock grant vested: Nicholas P. Alvarez, Chief Acquisition Officer of LifeMD, acquired 100,000 common shares on 08/22/2025 as a result of a performance stock grant that vested. The shares were issued at a $0 price, reflecting a vesting award rather than a purchased transaction. Following this vesting, Alvarez beneficially owns 680,000 common shares in total, held directly. The Form 4 was signed on 08/26/2025.
Insider Form 4 summary: Shayna Webb Dray, listed as Chief Operating Officer and a director-level reporting person at LifeMD, Inc., reported an acquisition on 08/22/2025 of 30,000 shares of the issuer's common stock through the vesting of performance stock. The transaction price is reported as $0, and following the vesting Dray beneficially owns 295,000 shares. The Form 4 was signed on 08/26/2025. The filing indicates the shares were granted as performance stock that vested on the transaction date.
LifeMD, Inc. reported another change in its independent auditor and highlighted ongoing internal control weaknesses. On August 15, 2025, with Audit Committee approval, the company dismissed CBIZ CPAs P.C., which had only been appointed in April 2025 and never issued an audit report.
On August 18, 2025, LifeMD appointed PricewaterhouseCoopers LLP (PwC) as its independent registered public accounting firm for the year ending December 31, 2025. The company states it has not previously consulted PwC on accounting or auditing matters. LifeMD also disclosed material weaknesses in internal control over financial reporting related to IT general controls, review of key third-party SOC reports, and business process controls over information produced by the company and evidence of formal review procedures.